Euroespes, S.A (EEP) Fair Value & Analysis
Healthcare · ES · Market cap €3.9M
Fair value as of: Jun 25, 2026
Analysis
Euroespes, S.A (EEP) currently trades at €0.3400, while our model-based Fair Value estimate is €0.2800 — implying the stock looks roughly 17.6% overvalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
About the company
Euroespes, S.A., a medical center, provides medical services for the research, diagnosis, and treatment of central nervous system disorders and other diseases in Spain and internationally. It offers personalized and genomic medicine services for predictive, diagnostic, and therapeutic purposes. The company also provides medical services, such as neuro-ophthalmology, neuro-otorhinolaryngology, neuropsychology, digital diagnostics, radiodiagnosis, clinical analysis laboratory, nursing, and cardiology. In addition, it researches and develops in the fields of biochemistry, health biotechnology, epigenetics, pharmacogenomics, and nutraceuticals. The company was founded in 1991 and is based in Corunna, Spain.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Euroespes, S.A (EEP) undervalued?
What is the fair value of EEP?
What is the quality score of EEP?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.